✦ LIBER ✦

257 UPDATED DATA FROM A PHASE 3 TRIAL OF EVEROLIMUS (RAD001) VERSUS PLACEBO IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

✍ Scribed by A. Kay; R.J. Motzer; R.A. Figlin; B. Escudier; S. Oudard; C. Porta; T.E. Hutson; S. Bracarda; N. Hollaender; G. Urbanowitz; A. Ravaud

Book ID: 119619597
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 517 KB
Volume: 8
Category: Article
ISSN: 1569-9056
DOI: 10.1016/s1569-9056(09)60262-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 2 study with a daily regimen of

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

✍ Robert J. Amato; Jaroslaw Jac; Sarah Giessinger; Somyata Saxena; James P. Willis 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 184 KB 👁 2 views

719 EVEROLIMUS IN PATIENTS WITH METASTAT

719 EVEROLIMUS IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA: SUBGROUP ANALYSIS OF PATIENTS WITH A REDUCTION IN TUMOR BURDEN ENROLLED IN A RANDOMIZED, PLACEBO-CONTROLLED, PHASE II TRIAL

✍ S. Oudard; B. Escudier; T. Hutson; C. Porta; S. Bracarda; V. Grunwald; J. Thomps 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 194 KB

Dynamic tumor modeling of the dose–respo

Dynamic tumor modeling of the dose–response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial

✍ Andrew Stein, Wenping Wang, Alison A Carter, Ovidiu Chiparus, Norbert Hollaender 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 519 KB

Axitinib versus sorafenib as first-line

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial

✍ Hutson, Thomas E; Lesovoy, Vladimir; Al-Shukri, Salman; Stus, Viktor P; Lipatov, 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 317 KB

7127 Results from additional analyses of

7127 Results from additional analyses of patient reported outcomes in RECORD-1 – a randomized trial of everolimus with metastatic renal cell carcinoma patients

✍ Beaumont, J.; Cella, D.; Hollaender, N.; Zheng, J.; Baladi, J.F.; Hutson, T. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 51 KB

Phase II Randomized Trial Comparing Sequ

Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma

✍ Motzer, R. J.; Barrios, C. H.; Kim, T. M.; Falcon, S.; Cosgriff, T.; Harker, W. 📂 Article 📅 2014 🏛 American Society of Clinical Oncology 🌐 English ⚖ 282 KB